Rankings
▼
Calendar
CPRX Q3 2024 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
CPRX
Catalyst Pharmaceuticals, Inc.
$3B
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$129M
+25.3% YoY
Gross Profit
$109M
85.0% margin
Operating Income
$51M
39.6% margin
Net Income
$44M
34.1% margin
EPS (Diluted)
$0.35
QoQ Revenue Growth
+4.9%
Cash Flow
Operating Cash Flow
$73M
Free Cash Flow
$73M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$772M
Total Liabilities
$111M
Stockholders' Equity
$661M
Cash & Equivalents
$442M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$129M
$103M
+25.3%
Gross Profit
$109M
$89M
+23.6%
Operating Income
$51M
-$37M
+236.9%
Net Income
$44M
-$31M
+242.6%
Revenue Segments
Product Revenue Net
$126M
98%
License And Other Revenue
$2M
2%
← FY 2024
All Quarters
Q4 2024 →